SavedAdd your journal

Journals / Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi / 2016 / Cilt: 13 - Sayı: 3

Biochemical Aneuploidy Screening Tests

Biyokimyasal Aneoploidi Tarama Testleri

Candan DUVAN
Ayla ESER
Nilüfer AKGÜN
Pages
125–129
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review emphasized that determining the most appropriate test for the detection of trisomy according to the gestational age and focus on the anomaly detection achiecvements of these tests.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Screening tests are used to detect high risk for a certain disease or anomalies.
📊
Key Findings & Data:In order to have healthy children, screening test is applied to find out directly to determine the anomalous babyWhile a good screening test is easily applicable, high reliabile and cost-effective.
💡
Conclusion & Impact:This review emphasized that determining the most appropriate test for the detection of trisomy according to the gestational age and focus on the anomaly detection achiecvements of these tests.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Gebelik · trizomiler · tarama testleri

Abstract

Screening tests are used to detect high risk for a certain disease or anomalies. In order to have healthy children, screening test is applied to find out directly to determine the anomalous babyWhile a good screening test is easily applicable, high reliabile and cost-effective. This review emphasized that determining the most appropriate test for the detection of trisomy according to the gestational age and focus on the anomaly detection achiecvements of these tests.

Özet

Tarama testleri belli bir hastalık riski veya anomali için yüksek riskli grubu saptamak amacı ile kullanılan testlerdir. Tarama testlerinin amacı sağlıklı çocuk sahibi olabilmek için en erken zamanda anomalili bebeği saptamaktır. İyi bir tarama testi kolay uygulanabilir, güvenirliği yüksek ve maliyeti düşük olmalıdır. Bu derlemenin amacı, Trizomilerin saptanması için en uygun testin gebelik haftasına göre belirlenmesi ve testlerin anomali saptama başarıları üzerinde durulacaktır.

🔖

Cite This Article

DUVAN, C., ESER, A., AKGÜN, N. (2022). Biochemical Aneuploidy Screening Tests. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi, Cilt: 13 - Sayı: 3, 125–129. https://ajindex.com/articles/558811

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Driscoll DA1, Gross S. Clinical practice. Prenatal screening for aneuplo- idy.N Engl J Med. 2009: 11;360:2556-62.
  2. Collins VR, Muggli EE, Riley M, et al. Is Down syndrome a disappearing birth defect? J Pediatr 2008; 152:20 Weisz B1, Rodeck CH.An update on antenatal screening for Down’s sy- ndrome and specific implications for assisted reproduction pregnancies. Hum Reprod Update. 2006;12:513-8.
  3. Tabor A, Alfirevic Z. Update on procedure-related risks for prenatal diag- nosis techniques. Fetal Diagn Ther 2010;27:17. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 88, December 2007. Invasive prenatal testing for aneuploidy. Obstet Gynecol. 2007;110:1459-67. Resta RG. Changing demographics of advanced maternal age (AMA) and the impact on the predicted incidence of Down syndrome in the United States: Implications for prenatal screening and genetic counseling. Am J Med Genet A 2005; 133:31. Ekelund CK, Jİrgensen FS, Petersen OB, et al. Impact of a new national screening policy for Down’s syndrome in Denmark: population based cohort study. BMJ 2008; 337:2547. Malone FD1, Canick JA, Ball RH, First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med. 2005 Nov 10;353:2001-11.
  4. Wald NJ, George L, Smith D, et al. Serum screening for Down’s syndro- me between 8 and 14 weeks of pregnancy. International Prenatal Scree- ning Research Group. Br J Obstet Gynaecol 1996; 103:407. Nicolaides KH. Nuchal translucency and other first-trimester sonograp- hic markers of chromosomal abnormalities. Am J Obstet Gynecol 2004; 191:45. Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH. Prospective validation of first-trimester combined screening for trisomy 21. Ultra- sound Obstet Gynecol 2009;34:14-18. Schielen PC, van Leeuwen-Spruijt M, Belmouden I, et al. Multi-centre first-trimester screening for Down syndrome in the Netherlands in routine clinical practice. Prenat Diagn 2006; 26:711. Hermann M, Fries N, Mangione R, et al. Nuchal translucency measure- ment: are qualitative and quantitative quality control processes related? Prenat Diagn 2013; 33:770. UptoDate 2014 Down syndrome:Prenatal screening overview Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson First and second trimester antenatal screening for Down’s syndrome: the re- sults of the Serum, Urine and Ultrasound Screening Study (SURUSS). AM.J Med Screen. 2003;10:56-104
  5. Breathnach FM, Malone FD, Lambert-Messerlian G, Cuckle HS, Por- ter TF, Nyberg D